CFChloe Frewen

Chloe Frewen

*This is an algorithmically generated author record based on publicly available information.

Chloe Frewen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Maintaining Enzyme Activity During Deposition Using a Cold Atmospheric Plasma System

    by Chloe Frewen, Cian Madigan, Liam O'NEill

    Even under benign conditions, plasma deposition of biological compounds has been shown to cause significant degradation and partial loss of functionality due to oxidation, fragmentation and other reactions. This study investigated the degradation effects of non‐thermal plasma deposition on an enzyme, Horseradish Peroxidase (HRP), with and without an antioxidant to mitigate degradation. This study clearly identified that plasma had a significant effect on the enzyme HRP and that the antioxidant protects the enzyme from degradation in a dose‐dependent manner. These findings suggest that plasma deposition can be optimised by incorporating antioxidants, potentially extending the application of plasma technology to sensitive biological materials. This approach holds promise for enhancing the practical use of plasma coating in diagnostic applications.

  • Open Access

    Cold Plasma Deposition of Tobramycin as an Approach to Localized Antibiotic Delivery to Combat Biofilm Formation

    by Beatrice Olayiwola, Fiona O’neill, Chloe Frewen, Darren F. Kavanagh, Rosemary O’hara, Liam O’neill

    Hospital-acquired infections (HAIs) remain a significant factor in hospitals, with implant surfaces often becoming contaminated by highly resistant strains of bacteria. Recent studies have shown that electrical plasma discharges can reduce bacterial load on surfaces, and this approach may help augment traditional antibiotic treatments. To investigate this, a cold atmospheric plasma was used to deposit tobramycin sulphate onto various surfaces, and the bacterial growth rate of K. pneumoniae in its planktonic and biofilm form was observed to probe the interactions between the plasma discharge and the antibiotic and to determine if there were any synergistic effects on the growth rate. The plasma-deposited tobramycin was still active after passing through the plasma field and being deposited onto titanium or polystyrene. This led to the significant inhibition of K. pneumoniae, with predictable antibiotic dose dependence. Separate studies have shown that the plasma treatment of the biofilm had a weak antimicrobial effect and reduced the amount of biofilm by around 50%. Combining a plasma pre-treatment on exposed biofilm followed by deposited tobramycin application proved to be somewhat effective in further reducing biofilm growth. The plasma discharge pre-treatment produced a further reduction in the biofilm load beyond that expected from just the antibiotic alone. However, the effect was not additive, and the results suggest that a complex interaction between plasma and antibiotic may be at play, with increasing plasma power producing a non-linear effect. This study may contribute to the treatment of infected surgical sites, with the coating of biomaterial surfaces with antibiotics reducing overall antibiotic use through the targeted delivery of therapeutics.